Subscribe
g0d4ather-shutterstock-com-amgen-
g0d4ather / Shutterstock.com
4 May 2023AmericasMuireann Bolger

Amgen sues generic drug maker over bone treatments

Lawsuit concerns multibillion-dollar bone-strengthening drugs | Alleged dearth of information provided to patent owner before biologics licence application was approved.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
AbbVie and Amgen settle Humira clash
29 September 2017   AbbVie has settled its patent dispute over Amgen’s proposed biosimilar for Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.
Americas
Amgen and Sandoz face off again over biosimilars
3 March 2016   Amgen and Sandoz are set to go head to head in another patent case, this time centring on Amgen’s arthritis treatment drug Enbrel.


Editor's picks

Americas
Comparing life sciences IP in Brazil and the US
28 November 2024

Editor's picks

Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024

More on this story

Americas
AbbVie and Amgen settle Humira clash
29 September 2017   AbbVie has settled its patent dispute over Amgen’s proposed biosimilar for Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.
Americas
Amgen and Sandoz face off again over biosimilars
3 March 2016   Amgen and Sandoz are set to go head to head in another patent case, this time centring on Amgen’s arthritis treatment drug Enbrel.

More on this story

Americas
AbbVie and Amgen settle Humira clash
29 September 2017   AbbVie has settled its patent dispute over Amgen’s proposed biosimilar for Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.
Americas
Amgen and Sandoz face off again over biosimilars
3 March 2016   Amgen and Sandoz are set to go head to head in another patent case, this time centring on Amgen’s arthritis treatment drug Enbrel.

More features

LSPN Europe: Navigating the EPO and lessons from the UPC’s frontline
Paul Hastings reinforces London office with high-tech patent litigator
Gene tech firm fends off injunction in test kit dispute
Comparing life sciences IP in Brazil and the US
Gilead awarded $30m over counterfeit HIV drug scheme
EPO invalidates human milk patent after Nestle opposition
Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings